Publication: A double-blind placebo-controlled study of an infusion of lexipafant (platelet-activating factor receptor antagonist) in patients with severe sepsis
1
Issued Date
2000-03-01
Resource Type
ISSN
00664804
Other identifier(s)
2-s2.0-0033994026
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Antimicrobial Agents and Chemotherapy. Vol.44, No.3 (2000), 693-696
Suggested Citation
Yupin Suputtamongkol, Sunanta Intaranongpai, Michael D. Smith, Brian Angus, Wipada Chaowagul, Chairat Permpikul, Julie A. Simpson, Amorn Leelarasamee, Lloyd Curtis, Nicholas J. White A double-blind placebo-controlled study of an infusion of lexipafant (platelet-activating factor receptor antagonist) in patients with severe sepsis. Antimicrobial Agents and Chemotherapy. Vol.44, No.3 (2000), 693-696. doi:10.1128/AAC.44.3.693-696.2000 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/26277
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
A double-blind placebo-controlled study of an infusion of lexipafant (platelet-activating factor receptor antagonist) in patients with severe sepsis
Abstract
Platelet-activating factor (PAF) is a potent endogenous proinflammatory mediator implicated in the pathogenesis of septic shock. A double-blind randomized placebo-controlled trial of an intravenous PAF receptor antagonist (lexipafant) was conducted with 131 adult Thai patients with suspected severe sepsis (66 of whom had positive blood cultures). Detailed serial clinical, biochemical, and cytokine measurements were performed. Lexipafant treatment was well tolerated. The 28-day mortality in the lexipafant group (61.4%) was similar to that in the placebo group (62.6%). There was also no evidence that lexipafant affected clinical or biochemical measures of disease severity or the profile of sequentially measured plasma cytokine levels. PAF may not have an important role in the pathogenesis of severe sepsis.